Even if equities rise in 2025 on optimism surrounding AI, investor psychology mirrors that of prior generations—driven by the ...
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...
Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback